Immense interims from #NCYT. Notable points:
- Revenue increase YoY of 900%, to €72.4m
- 91% of revenue (~€66m) generated in Q2
- PAT margin of 56% (€40.2m). An extraordinary margin
- Inventory of €15.6m, trade receivables of €28.5m
- €8.3m debt paid off in period
1/3
- Revenue increase YoY of 900%, to €72.4m
- 91% of revenue (~€66m) generated in Q2
- PAT margin of 56% (€40.2m). An extraordinary margin
- Inventory of €15.6m, trade receivables of €28.5m
- €8.3m debt paid off in period
1/3
- Mgmt has specifically stated its intention to pursue M&A activities (hence Numis #NUM as new broker)
- Multiple new products recently launched, with more in development
All in all, in my view mgmt is DRASTICALLY under-promising on its full year guidance of "revenue to...
2/3
- Multiple new products recently launched, with more in development
All in all, in my view mgmt is DRASTICALLY under-promising on its full year guidance of "revenue to...
2/3
...exceed €150m and EBITDA to exceed €100m".
One would expect Q3 revenue to exceed Q2's of €66m; and Q4 to exceed Q3, given the increasing demand for #COVID19 testing, as well #NCYT's growing range of diagnostics.
Expecting a major re-rating now, supercharged by M&A.
3/3
One would expect Q3 revenue to exceed Q2's of €66m; and Q4 to exceed Q3, given the increasing demand for #COVID19 testing, as well #NCYT's growing range of diagnostics.
Expecting a major re-rating now, supercharged by M&A.
3/3
• • •
Missing some Tweet in this thread? You can try to
force a refresh
